METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 substrate, MATE1 substrate, MATE2-K substrate, and combinations thereof. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof. The therapeutically effective amount of the drug is not adjusted relative to a subject who is not being administered dichlorphenamide.
1 .- 22 . (canceled)
23 . A method for treating primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, or related variants in a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a P-gp substrate to treat a disease or disorder, the method comprising:
administering a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, to the subject,
wherein the therapeutically effective amount of the P-gp substrate is not adjusted relative to a subject who is being administered the P-gp substrate and is not being administered dichlorphenamide, or a pharmaceutically acceptable salt thereof.
24 . The method of claim 23 , further comprising informing the subject or a medical care worker that administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject who is also taking a P-gp substrate results in no increase in drug exposure as compared with administering the P-gp substrate to a subject who is not being administered dichlorphenamide, or a pharmaceutically acceptable salt thereof.
25 . The method of claim 23 , further comprising informing the subject or a medical care worker that administering dichlorphenamide, or a pharmaceutically acceptable salt thereof to a subject who is also taking a P-gp substrate may result in no increased risk of one or more exposure-related adverse reactions than administering the P-gp substrate to a subject who is not being administered dichlorphenamide, or a pharmaceutically acceptable salt thereof.
26 . The method of claim 23 , wherein the therapeutically effective amount of the dichlorphenamide, or a pharmaceutically acceptable salt thereof, is between 25 mg and 200 mg per day.
27 . The method of claim 23 , wherein the therapeutically effective amount of the dichlorphenamide, or a pharmaceutically acceptable salt thereof, is 50 mg twice daily.
28 . The method of claim 23 , wherein the dichlorphenamide, or a pharmaceutically acceptable salt thereof, is administered via a titration scheme that comprises the up-titration of the dichlorphenamide, or a pharmaceutically acceptable salt thereof, at weekly intervals until a modified dose is administered.
29 . The method of claim 23 , wherein the disease or disorder treated with the P-gp substrate is atrial fibrillation, atrial flutter, or heart failure.